Processa Pharmaceuticals, Inc.
$2.71
▲
6.42%
2026-04-21 08:46:01
www.processapharmaceuticals.com
NCM: PCSA
Explore Processa Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.25 M
Current Price
$2.71
52W High / Low
$19.63 / $1.76
Stock P/E
—
Book Value
$2.17
Dividend Yield
—
ROCE
-250.81%
ROE
-3.73%
Face Value
—
EPS
$-10.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
0.89
Debt / Equity
0
Current Ratio
2.54
Quick Ratio
2.54
Forward P/E
-0.74
Price / Sales
—
Enterprise Value
$1.83 M
EV / EBITDA
-0.13
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 2. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
| 3. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
| 4. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 5. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
| 6. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 7. | Cardio Diagnostics Holdings, Inc. | $1.97 | — | $5.95 M | — | -90.54% | -78.62% | $17.4 / $0.97 | $3.82 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.7 M | -3.49 M | -3.95 M | -2.85 M | -2.73 M | — |
| Net Profit | -3.36 M | -3.44 M | -3.93 M | -2.83 M | -2.73 M | — |
| EPS in Rs | -1.26 | -1.29 | -1.48 | -1.07 | -1.03 | -25.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.99 M | -12.05 M | -11.46 M | -20.26 M |
| Net Profit | -13.56 M | -11.85 M | -11.12 M | -27.42 M |
| EPS in Rs | -5.1 | -4.45 | -4.18 | -10.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.81 M | 3.23 M | 5.79 M | 8.62 M |
| Total Liabilities | 2.24 M | 1.53 M | 0.8 M | 1.15 M |
| Equity | 5.58 M | 1.7 M | 4.99 M | 7.47 M |
| Current Assets | 5.67 M | 1.88 M | 5.63 M | 8.39 M |
| Current Liabilities | 2.24 M | 1.53 M | 0.73 M | 1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.39 M | -11.25 M | -8.06 M | -9.61 M |
| Investing CF | -0.85 M | -0 M | -0 M | 0 M |
| Financing CF | 16.58 M | 7.73 M | 6.27 M | -0.39 M |
| Free CF | -12.24 M | -11.25 M | -8.07 M | -9.61 M |
| Capex | -0.85 M | -0 M | -0 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -6.55% | 59.45% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-17 | 1:0.04 |
| 2024-01-22 | 1:0.05 |